Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vaccitech, an Oxford University spinout company developing a universal flu vaccine has secured £20 million in Series A financing.

person getting a flu jab

The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences Innovation, which manages a £600m fund aimed at Oxford University spinouts, and was also joined by Neptune Ventures. This brings the total amount raised by Vaccitech to £30 million since it was established in 2016. Vaccitech is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at the Jenner Institute.

Read the full article

Similar stories

Establishing African epidemic and pandemic sciences networks

The Pandemic Sciences Institute has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.